menu
    • menu
    [{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Atrogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATR-258","moa":"Insulin signaling","graph1":"Endocrinology","graph2":"Phase I","graph3":"Atrogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atrogi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atrogi \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Atrogi

                            Sweden arrow
                            Pharmex
                            Not Confirmed

                            Atrogi

                            Sweden arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-258

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atrogi Reports Positive Data from First-in-Class Diabetes Treatment

                            Details : ATR-258 binds to the beta-2-adrenoceptor to facilitate glucose transportation into skeletal muscle, lowering blood glucose levels and positively affecting several organs in Type 2 diabetes.

                            Product Name : ATR-258

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 14, 2024

                            Lead Product(s) : ATR-258

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vicore Pharma

                            Sweden arrow
                            Pharmex
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction

                            Details : C21 is an angiotensin II type 2 receptor agonist, which s being developed for the treatment endothelial dysfunction (reflecting blood vessel health) in patients with type-2-diabetes-mellitus.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 05, 2023

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth